Medincell : Une base solide pour de nouvelles ambitions
Dans le cadre du Forum ODDO BHF, nous avons eu l’occasion de revenir sur les ambitions à court et moyen termes du management. Aussi, les prochains mois de Medincell devraient être transformants avec 1/ la montée en puissance des ventes d’Uzedy, 2/ le lancement d’Olanzapine LAI considéré par son partenaire Teva comme un blockbuster et 3/ l’entrée en clinique de son 1er candidat médicament venant de son partenariat avec Abbvie. Ces milestones commerciaux, réglementaires et cliniques devraient permettre de soutenir le cours et rassurer les investisseurs sur la capacité du groupe à maintenir la dynamique. Nous maintenons notre recommandation à Surperformance et ajustons notre OC de 27 € à 34€.Medincell SA. Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.